Abstract Aim To investigate glycaemic outcomes in youths and adults with type 1 diabetes with either MiniMed™ 780G or Tandem t:slim X2™ control‐IQ automated insulin delivery (AID) systems and to evaluate clinical factors that migrate, mitigate the achievement of therapeutic goals. Materials and Methods This retrospective, real‐world, observational study was conducted in a specialized university type 1 diabetes centre with patients observed for 3‐12 months post‐initiation of an AID system. Primary outcomes were the percentage time in the target glucose range [TIR 70‐180 mg/dl (3.9‐10 mmol/L)] as measured by continuous glucose monitoring, mean glucose management indicator (GMI) and glycated haemoglobin (HbA1c) levels. Results Our study cohort consisted of 48 adolescents and 183 adults (55% females) aged 10‐77 years. The mean (95% confidence interval) TIR 70‐180 mg/dl after 30 days was higher than baseline and by 14% points after 360 days with 71.33% (69.4‐73.2) (n = 123, p < .001). HbA1c levels decreased by 0.7% and GMI by 0.6% after 360 days. The proportion of time spent <70 mg/dl (3.9 mmol/L) was not significantly different from baseline. During follow‐up, 780G users had better continuous glucose monitoring results than control‐IQ users but similar HbA1c levels, and an increased risk of weight gain. Age at onset influenced TIR 70‐180 mg/dl in univariate analysis but there was no significant relationship after adjusting on explanatory variables. Baseline body mass index did not influence the performance of AID systems. Conclusions This analysis showed the beneficial effects of two AID systems for people with type 1 diabetes across a broad spectrum of participant characteristics. Only half of the participants achieved international recommendations for glucose control with TIR 70‐180 mg/dl >70%, HbA1c levels or GMI <7%, which outlines the need to maintain strong educational and individual strategies.